ACI WORLDWIDE, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ACI WORLDWIDE, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $1.01B | Mar 1, 2019 |
| FY2018 | Dec 31, 2017 | $1.02B | Mar 1, 2019 |
| FY2018 | Dec 31, 2016 | $1.01B | Mar 1, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.76B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.59B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.45B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.42B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $1.37B | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $1.29B | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $1.26B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $1.01B | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $1.02B | Feb 27, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $326.40M | Feb 27, 2018 |
| FY2017 | Sep 30, 2017 | $225.74M | Feb 27, 2018 |
| FY2017 | Jun 30, 2017 | $240.60M | Feb 27, 2018 |
| FY2017 | Mar 31, 2017 | $231.46M | Feb 27, 2018 |
| FY2017 | Dec 31, 2016 | $342.73M | Feb 27, 2018 |
| FY2017 | Sep 30, 2016 | $216.98M | Feb 27, 2018 |
| FY2017 | Jun 30, 2016 | $219.93M | Feb 27, 2018 |
| FY2017 | Mar 31, 2016 | $226.07M | Feb 27, 2018 |
| FY2016 | Dec 31, 2015 | $308.64M | Mar 1, 2017 |
| FY2016 | Sep 30, 2015 | $238.70M | Mar 1, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $226.66M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $203.12M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $121.51M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $142.18M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $127.79M | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | $67.15M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $15.87M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $14.08M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | ($24.43M) | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $55.49M | Feb 25, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $329.91M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $308.14M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $220.41M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $203.84M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $209.90M | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | $95.71M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $31.18M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $29.14M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | ($11.28M) | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $102.41M | Feb 25, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2010 | Dec 31, 2010 | $74.08M | Feb 18, 2011 |
| FY2010 | Dec 31, 2009 | $77.51M | Feb 18, 2011 |
| FY2010 | Dec 31, 2008 | $75.85M | Feb 18, 2011 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $322.83M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $358.75M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $168.52M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $143.38M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $220.47M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $314.90M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $132.61M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $183.93M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $146.20M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $99.83M | Mar 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.91M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $15.40M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $8.92M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $13.10M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $20.58M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $17.80M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $23.10M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $18.27M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $25.72M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $40.81M | Mar 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.10B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.03B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $3.44B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $3.21B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $3.16B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $3.39B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $3.26B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $2.12B | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $1.86B | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $1.90B | Feb 27, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.59B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.60B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $2.12B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $2.02B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.91B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $2.18B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $2.13B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $1.07B | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $1.10B | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $1.15B | Feb 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.52B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.42B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.32B | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $1.19B | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $1.24B | Feb 27, 2025 |
| FY2023 | Dec 31, 2020 | $1.21B | Feb 29, 2024 |
| FY2022 | Dec 31, 2019 | $1.13B | Mar 1, 2023 |
| FY2021 | Dec 31, 2018 | $1.05B | Feb 24, 2022 |
| FY2020 | Dec 31, 2017 | $764.60M | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | $754.92M | Feb 27, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.23B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.23B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.23B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.23B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.28B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $1.28B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $1.28B | Feb 25, 2021 |
| FY2020 | Dec 31, 2018 | $909.69M | Feb 25, 2021 |
| FY2018 | Dec 31, 2017 | $909.69M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $909.69M | Feb 27, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.82B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.60B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.39B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.27B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.13B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $1.00B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $930.83M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $863.77M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $550.87M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $545.73M | Feb 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $196.46M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $216.39M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $164.24M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $124.98M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $122.06M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $165.37M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $121.40M | Feb 24, 2022 |
| FY2019 | Dec 31, 2018 | $148.50M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $69.71M | Mar 1, 2019 |
| FY2018 | Dec 31, 2016 | $75.75M | Mar 1, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $817.61M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $924.58M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.04B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.09B | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $1.07B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $1.16B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $1.37B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $671.76M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $685.73M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $743.92M | Feb 27, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 25, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 25, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 102.71M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 105.25M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 108.08M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 108.07M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 115.73M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 117.11M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 115.99M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 116.12M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | 117.10M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | 117.34M | Feb 27, 2018 |